LAVA Therapeutics NV LVTX.OQ LVTX.O is expected to show no change in quarterly revenue when it reports results for the period ending June 30 2025
LSEG's mean analyst estimate for LAVA Therapeutics NV is for a loss of 31 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 20.8% in the last three months.
Wall Street's median 12-month price target for LAVA Therapeutics NV is $1.50, above its last closing price of $1.26.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.38 | -0.38 | -0.13 | Beat | 66 |
Dec. 31 2025 | -0.21 | -0.29 | -0.14 | Beat | 52.5 |
Sep. 30 2024 | -0.35 | -0.33 | -0.46 | Missed | -39.4 |
Jun. 30 2024 | -0.37 | -0.36 | -0.31 | Beat | 13.9 |
Mar. 31 2024 | -0.11 | -0.12 | -0.02 | Beat | 84 |
Dec. 31 2023 | 0.33 | -0.12 | -0.24 | Missed | -92 |
Sep. 30 2023 | -0.49 | -0.49 | -0.34 | Beat | 30.6 |
Jun. 30 2023 | -0.47 | -0.47 | -0.48 | Missed | -1.4 |
This summary was machine generated May 16 at 12:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。